How should alopecia areata be treated in an unmarried 30‑year‑old female patient?

Treatment of Alopecia Areata in a 30-Year-Old Unmarried Female

For a 30-year-old female with alopecia areata, intralesional corticosteroid injections are the first-line treatment for limited patchy disease, while JAK inhibitors (baricitinib or ritlecitinib) should be initiated for severe disease (≥50% scalp involvement). 1, 2

Treatment Algorithm Based on Disease Severity

For Limited Patchy Disease (<50% scalp involvement)

Intralesional corticosteroids are the gold standard first-line therapy for localized alopecia areata in adults, particularly for cosmetically sensitive areas. 1, 3

• Triamcinolone acetonide (5-10 mg/mL) injected just beneath the dermis in the upper subcutis is most commonly used 1
• Each 0.05-0.1 mL injection produces approximately 0.5 cm diameter tuft of hair growth 1
• Monthly injections are administered, with 62% of patients achieving full regrowth when fewer than five patches of <3 cm diameter are present 1
• Response is better in patients with limited disease extent and shorter duration 1
• The effect typically lasts about 9 months 1
• Main limitation is patient discomfort during the procedure 1, 4

Alternative first-line options for limited disease:

• Very potent topical corticosteroids (clobetasol propionate 0.05% foam) can be used if injections are not tolerated, though efficacy is more limited 1, 4
• In one RCT, 7 of 34 sites treated with clobetasol foam achieved ≥50% regrowth versus 1 of 34 with vehicle after 12 weeks 1
• Folliculitis is a common side effect of potent topical steroids 1

For Moderate to Severe Disease (≥50% scalp involvement or SALT score ≥20)

JAK inhibitors are now the treatment with the highest level of evidence for severe alopecia areata. 2, 3

• Baricitinib (JAK 1/2 inhibitor) is FDA and EMA-approved for adults with severe alopecia areata 2, 5
• Ritlecitinib (JAK 3/TEC inhibitor) is approved for individuals aged 12 and older with severe disease 2, 5
• Deuruxolitinib is the third oral JAK inhibitor approved by the FDA in July 2024 for severe AA in adults 5
• These medications target the IFN-γ-driven immune response and cytotoxic CD8 T cells that drive disease pathogenesis 6
• Treatment duration should be at least 6-12 months, as some patients may not respond until after prolonged therapy 7
• If one JAK inhibitor fails, switching to another within the class may be successful 7

Alternative systemic options if JAK inhibitors are unavailable or contraindicated:

• Systemic corticosteroids (short-term pulse therapy) 2, 3
• Cyclosporine, methotrexate, or azathioprine as corticosteroid-sparing immunosuppressants 2, 3
• Contact immunotherapy with DPCP (diphenylcyclopropenone) for stable extensive cases, though this requires specialized centers 1, 3

Special Considerations for This Patient Population

For a 30-year-old unmarried female, quality of life and cosmetic outcomes are particularly important:

• Hair loss significantly impacts quality of life, especially in young women 2
• Eyebrow involvement should be specifically treated with intralesional corticosteroids regardless of scalp disease extent, as this is cosmetically sensitive 1
• If disease is longstanding and extensive (alopecia totalis/universalis), wigs may be a better option than treatments unlikely to be effective, as full recovery occurs in <10% of these cases 1

Adjuvant Therapy

• Oral minoxidil can be considered as adjuvant therapy, though data on efficacy are limited 2
• Topical minoxidil (1-3%) has shown inconsistent results in controlled trials, with response rates of 32-33% in extensive disease but <10% sustained benefit 1

Prognostic Factors to Discuss

Disease severity at presentation is the strongest predictor of long-term outcome: 1

• 68% of patients with <25% hair loss initially report being disease-free at long-term follow-up 1
• Only 8% with >50% initial hair loss achieve complete remission 1
• 14-25% progress to alopecia totalis/universalis, from which full recovery is unusual 1
• Almost all patients experience more than one episode of the disease 1

Common Pitfalls to Avoid

• Do not delay systemic therapy in patients with rapidly progressive or extensive disease (≥50% involvement), as early intervention may improve outcomes 2, 3
• Do not discontinue JAK inhibitors prematurely—some patients require 12+ months to see robust response 7
• Avoid prolonged PUVA therapy due to high cumulative UVA doses and high relapse rates 1
• Reassurance alone is appropriate only for recent-onset limited disease (<1 year duration), with counseling that regrowth cannot be expected within 3 months of any individual patch 1